Aptalis Pharma taps NuMedii to Select Candidates for Drug Research | GenomeWeb

NuMedii said this week that it will use its predictive platform to identify potential therapeutic candidates for gastrointestinal disorders and cystic fibrosis for Aptalis Pharma.

Under the terms of the collaboration, NuMedii will provide proprietary, de-risked drug candidates, while Aptalis will handle the development and commercialization of the treatments it chooses to pursue.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: role for RNA splicing in genetic variation, and more.

An advocacy group sues the US Food and Drug Administration over redactions of information about advisory committee members, Stat News reports.

Mexico is trying to lure young genomics researchers back home with their own labs, Science reports.

A molecular autopsy has aided a woman's search for why sudden cardiac death has stalked her family, the Wall Street Journal reports.